NeuroAge Therapeutics focuses on developing and validating diagnostic biomarkers for the early detection of Alzheimer’s disease and related dementias. The company's core work is centered on biomarker discovery and validation to improve early diagnosis. Recently, NeuroAge announced it received $250K in funding from the Alzheimer's Drug Discovery Foundation’s Diagnostics Accelerator (DxA). That funding is intended to support the development and validation activities tied to early‑detection biomarkers. The Diagnostics Accelerator is described as a $100 million global research initiative created in July 2018 and backed by major philanthropists and foundations. No operating metrics or additional financial details were provided in the article.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2024